Specialty Pharma Journal Specialty, Precision & Technology
GENEVA, Dec. 14, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA (prostate stem …
Tag Archives: car-t
December, 2018
-
5 December
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Study of Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Multiple Myeloma
CAMBRIDGE, Mass. & SUMMIT, N.J.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented by Nina Shah, M.D., …
November, 2018
-
21 November
Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome and Neurotoxicity
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced the publication of a preclinical study of its ARTEMIS antibody-TCR (AbTCR) Receptor Platform in Cell Discovery. The data in this publication …
-
9 November
Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., a biotechnology company developing cell therapies with pharmacologic operating systems, today announced the presentation of preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains (DDs) paired with FDA-approved small molecule drugs. Obsidian will reveal a suite of novel human DDs …
-
7 November
Sorrento’s Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity with Increased Overall Survival in Pancreatic Cancer Patients with Liver Metastases
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for …
June, 2018
-
25 June
AbbVie and Calibr Collaborate for Development of Next Generation T-Cell Therapies
NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie’s oncology research to access advanced precision …
-
13 June
Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy
NEW YORK–(BUSINESS WIRE)–Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced the publication of a study in Scientific Reports, a Nature Publishing Group journal, describing the development of the CubiCAR, an all-in-one Chimeric Antigen Receptor (CAR) architecture with an …
-
5 June
Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers
CHICAGO–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results include analyses of the ZUMA-1 study of …
-
1 June
Amgen and MD Anderson Announce Two Collaboration Agreements to Accelerate Development of Various Cancer Therapies
THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies …
May, 2018
-
14 May
Medigene Expands T-Cell Receptor Deal with Bluebird bio to up to $1.5 Billion
Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, today announced the significant expansion of its successful strategic alliance with bluebird bio, a leader in gene and cell therapies, focusing on the research and development of T cell receptor-modified T cell (TCR-T) immunotherapies for the treatment of cancer. “We are delighted to …